Progress in classification of hypereosinophilic syndrome --- review.
- Author:
Zhi-Ming AN
1
;
Yong-Ping ZHAI
Author Information
1. Department of Hematology, Nanjing General Hospital, Nanjing Military Area, Nanjing, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Hypereosinophilic Syndrome;
classification;
therapy
- From:
Journal of Experimental Hematology
2011;19(4):1087-1091
- CountryChina
- Language:Chinese
-
Abstract:
Hypereosinophilic syndromes (HES) are a heterogeneous group of uncommon disorders which characterized by marked peripheral eosinophilia and function damage of target organ, with different etiologies, mechanisms and therapies in different subtypes. Formerly the prognosis was very poor, nowadays with great development in science and medicine, we can understand HES much better in classification, diagnosis and therapy, including the development of novel targeted therapies, such as tyrosine kinase inhibitors and humanized monoclonal antibodies, which increased the treatment selection and complexity of therapeutic decisions in HES. This review discusses the classification of HES and characters of different subtypes, including therapeutic methods, which can help clinical doctors to have a good understanding of HES.
